Stockchase Opinions

The Panic-Proof Portfolio (Stockchase Research) Vertex Pharmaceuticals Inc. VRTX-Q PAST TOP PICK Nov 07, 2023

(A Top Pick Jan 04/22, Up 88.8%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $330) to $350 at this time.  

$383.015

Stock price when the opinion was issued

Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

BUY

Likes it for its CF franchise.

BUY

This drugmaker has a lock on MS and have new shots on pain management and other maladies. Lots going on. Up sharply this month.

HOLD

It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.

HOLD

Even at this all time high don't sell. They're working on non-addictive painkillers

BUY

Negative free cash flow to enter 2024, but it's turning positive. Shares are up 21% this year.

BUY

Their anti-pain drug is not addictive and it works. He's a believer.

BUY ON WEAKNESS

He likes it for developing non-addictive painkillers with potential FDA approvals ahead. They reported a great quarter a day before the election, but has since pulled back hard that baffles him. Looks like profit-taking in a stock that's jumped 113% since end-2021.

DON'T BUY

They got disappointing news on their wonder drug. Disappointing. Doesn't see upside for the company.

PARTIAL SELL

She trimmed it because it's up 20% this year because of the launch of their pain medicine. Tonight's earnings will be fine and their pipeline makes it a good stock long term.

BUY

A strong performer in this market, not pulling back. Everybody is excited over their pain drug, and other drugs in the pipeline as well.